FCGR3B and acute myeloid leukemia: To do this, we have developed a blocker that targets a non-HLA-I molecule, in this case CD16b, and paired it with a CD33 CAR to create a CD33 | CD16b Tmod construct that selectively kills CD33(+)CD16b(-) AML cells, but spares isogenic cells that express CD16b, in vitro and in vivo.